Prime Medicine, Inc. Common Stock
PRMEPrime Medicine, Inc. (PRME) is a biotechnology company focused on developing gene editing therapies for genetic diseases. Leveraging its Prime Editing technology, the company aims to create precise, efficient, and versatile treatments to address a range of genetic conditions, with an emphasis on improving patient outcomes through innovative genomic editing solutions.
Dividend History
| Pay Date | Amount | Ex-Date | Record Date |
|---|---|---|---|
| September 12, 2019 | $0.80 | 2019-09-10 | 2019-09-11 |
| June 28, 2019 | $0.20 | 2019-06-14 | 2019-06-17 |
| December 31, 2018 | $0.21 | 2018-12-18 | 2018-12-19 |
| September 28, 2018 | $0.23 | 2018-09-14 | 2018-09-17 |
| June 29, 2018 | $0.15 | 2018-06-21 | 2018-06-22 |
Dividends Summary
- Consistent Payer: Prime Medicine, Inc. Common Stock has rewarded shareholders with 15 dividend payments over the past 4 years.
- Total Returned Value: Investors who held PRME shares during this period received a total of $3.84 per share in dividend income.
- Latest Payout: The most recent dividend of $0.80/share was paid 2325 days ago, on September 12, 2019.
- Yield & Schedule: PRME currently pays dividends quarterly with an annual yield of 30.93%.
- Dividend Growth: Since 2015, the dividend payout has grown by 820.6%, from $0.09 to $0.80.
Company News
The gene therapy market is projected to reach $36.55 billion by 2032, with the FDA approving three transformative cell therapies in December. Five biotech companies are advancing therapies across diabetes, sickle cell disease, cardiovascular disease, liver disease, and chronic granulomatous disease, with recent clinical data demonstrating signifi...
Prime Medicine published Phase 1/2 clinical data for PM359, an investigational gene therapy for chronic granulomatous disease, demonstrating safety and early clinical efficacy in two patients with promising results in neutrophil restoration and disease symptom improvement.
Prime Medicine reported Q3 2025 financial results, highlighting progress in genetic therapies for Wilson's Disease and Alpha-1 Antitrypsin Deficiency, with plans to file IND/CTA applications in 2026-2027 and new preclinical data to be presented at AASLD.
Prime Medicine reported Q2 2025 earnings with a net loss of $52.6 million, below analyst estimates. The company demonstrated clinical proof-of-concept for Prime Editing in chronic granulomatous disease and extended its cash runway into 2027 through strategic restructuring and funding.
Prime Medicine is conducting a public offering of 38 million shares at $3.30 per share, expecting to raise approximately $125.4 million. The Cystic Fibrosis Foundation will purchase 1,818,181 shares, and the offering is expected to close on August 1, 2025.
